TY - JOUR T1 - Impact of January 2021 social distancing measures on SARS-CoV-2 B.1.1.7 circulation in France JF - medRxiv DO - 10.1101/2021.02.14.21251708 SP - 2021.02.14.21251708 AU - Laura Di Domenico AU - Chiara E. Sabbatini AU - Giulia Pullano AU - Daniel Lévy-Bruhl AU - Vittoria Colizza Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/16/2021.02.14.21251708.abstract N2 - Facing B.1.1.7 variant, social distancing was strengthened in France in January 2021. Using a 2-strain mathematical model calibrated on genomic surveillance, we estimated that social distancing allowed hospitalizations to plateau, by decreasing transmission of the historical strain while B.1.1.7 continued to grow. Variant dominance is expected by the end of February-early March in France, with large geographical heterogeneity. Without strengthened social distancing, a rapid surge of hospitalizations is expected in the next weeks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is partially funded by: ANR projects DATAREDUX (ANR-19-CE46-0008-03), EVALCOVID-19 (ANR-20-COVI-0007); EU H2020 grants MOOD (H2020-874850) and RECOVER (H2020-101003589); REACTing COVID-19 modeling grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available at the references cited. ER -